{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:38:00Z","timestamp":1760099880238},"reference-count":47,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1016\/j.ygyno.2006.07.036","type":"journal-article","created":{"date-parts":[[2006,9,8]],"date-time":"2006-09-08T19:25:10Z","timestamp":1157743510000},"page":"114-119","source":"Crossref","is-referenced-by-count":6,"title":["Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: A phase I study of the Gynecologic Oncology Group"],"prefix":"10.1016","volume":"104","author":[{"given":"Peter G.","family":"Rose","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin E.","family":"Greer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ira R.","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurie","family":"Markman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Fusco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2006.07.036_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2006.07.036_bib2","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/jnci\/92.9.699","article-title":"Randomized intergroup trial of cisplatin\u2013paclitaxel versus cisplatin\u2013cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results","volume":"92","author":"Piccart","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2006.07.036_bib3","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared to cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2006.07.036_bib4","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","article-title":"A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer","volume":"95","author":"du Bois","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2006.07.036_bib5","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1200\/JCO.1997.15.3.987","article-title":"Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation","volume":"15","author":"Muggia","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2006.07.036_bib6","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/JCO.1998.16.2.405","article-title":"et al Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study","volume":"16","author":"Rose","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2006.07.036_bib7","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1200\/JCO.1998.16.10.3345","article-title":"Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after chemotherapy that contained cisplatin or carboplatin and paclitaxel","volume":"16","author":"Bookman","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2006.07.036_bib8","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1006\/gyno.1996.0284","article-title":"Activity of Gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel","volume":"63","author":"Shapiro","year":"1996","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2006.07.036_bib9","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1200\/JCO.2000.18.16.2957","article-title":"A phase I study of paclitaxel, carboplatin and increasing doses of prolonged oral etoposide in ovarian, peritoneal, and tubal carcinoma: a Gynecologic Oncology Group study","volume":"18","author":"Rose","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2006.07.036_bib10","first-page":"1351a","article-title":"A Phase I study of topotecan, cisplatin and paclitaxel in newly diagnosed epithelial ovarian cancer, a Gynecologic Oncology Group study","volume":"17","author":"Armstrong","year":"1998","journal-title":"Proc. ASCO"},{"key":"10.1016\/j.ygyno.2006.07.036_bib11","first-page":"357a","article-title":"Gemcitabine, carboplatin, and paclitaxel (GCP) as first-line treatment of ovarian cancer FIGO stages IIB\u2013IV","volume":"18","author":"Hansen","year":"1999","journal-title":"Proc ASCO"},{"key":"10.1016\/j.ygyno.2006.07.036_bib12","first-page":"891","article-title":"Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes","volume":"52","author":"Gabizon","year":"1992","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2006.07.036_bib13","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2000.18.17.3093","article-title":"Phase II study of liposomal doxorubicin platinum- and paclitaxel-refractory epithelial ovarian carcinoma","volume":"18","author":"Gordon","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2006.07.036_bib14","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2006.07.036_bib15","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1200\/JCO.1991.9.9.1668","article-title":"Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis","volume":"9","author":"Ovarian Cancer Meta-analysis Project","year":"1991","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2006.07.036_bib16","first-page":"954","article-title":"Meta-analysis of cisplatin, doxorubicin, and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma","volume":"80","author":"Fanning","year":"1992","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2006.07.036_bib17","first-page":"15","article-title":"Paclitaxel (Taxol)\/doxorubicin combinations in advanced breast cancer: the Eastern Cooperative Oncology Group experience","volume":"21","author":"Sledge","year":"1994","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ygyno.2006.07.036_bib18","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1200\/JCO.1995.13.11.2688","article-title":"Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study","volume":"13","author":"Gianni","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2006.07.036_bib19","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1200\/JCO.1996.14.10.2713","article-title":"Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer","volume":"14","author":"Holmes","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2006.07.036_bib20","first-page":"1511","article-title":"Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium","volume":"7","author":"Minotti","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2006.07.036_bib21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1517\/14740338.2.1.59","article-title":"Cardiotoxic effects of anthracycline\u2013taxane combinations","volume":"2","author":"Perotti","year":"2003","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.ygyno.2006.07.036_bib22","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1023\/A:1008216430806","article-title":"The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin","volume":"9","author":"Berry","year":"1998","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2006.07.036_bib23","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1023\/A:1008365716693","article-title":"Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500\u00a0mg\/m2","volume":"11","author":"Safra","year":"2000","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2006.07.036_bib24","first-page":"33","article-title":"Interim analysis of a phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer","volume":"23","author":"Luck","year":"1996","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ygyno.2006.07.036_bib25","first-page":"28","article-title":"A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer","volume":"23","author":"Conte","year":"1996","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ygyno.2006.07.036_bib26","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1159\/000011977","article-title":"A phase I study of paclitaxel and epirubicin, without and with filgrastim, for the treatment of platinum-resistant advanced ovarian cancer","volume":"56","author":"Lauria","year":"1999","journal-title":"Oncology"},{"key":"10.1016\/j.ygyno.2006.07.036_bib27","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0090-8258(02)00151-8","article-title":"Epirubicin and paclitaxel (EPI-TAX regimen) for the advanced ovarian cancer after failure of platinum-containing regimens","volume":"88","author":"Ray-Coquard","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2006.07.036_bib28","first-page":"2917","article-title":"Docetaxel and epirubicin supported by granulocyte colony-stimulating factor first-line in advanced breast cancer","volume":"23","author":"Polyzos","year":"2003","journal-title":"Anticancer. Res."},{"key":"10.1016\/j.ygyno.2006.07.036_bib29","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1006\/gyno.1998.5237","article-title":"Paclitaxel vs epidoxorubicin plus paclitaxel as second-line therapy for platinum-refractory and -resistant ovarian cancer","volume":"72","author":"Bolis","year":"1999","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2006.07.036_bib30","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S0090-8258(03)00373-1","article-title":"Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Mullerian tumors","author":"Campos","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2006.07.036_bib31","first-page":"1817","volume":"10","author":"Rigatos","year":"2003","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ygyno.2006.07.036_bib32","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/cncr.11547","article-title":"Phase I dose and sequencing study of pegylated liposomal doxorubicin and docetaxel in patients with advanced malignancies","volume":"98","author":"Fracasso","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2006.07.036_bib33","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0959-8049(99)00309-3","article-title":"Combining platinum, paclitaxel and anthracycline in patients with advanced gynaecological malignancy","volume":"36","author":"Gregory","year":"2000","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2006.07.036_bib34","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1006\/gyno.1998.5205","article-title":"A phase I study of paclitaxel, doxorubicin, and cisplatin in patients with previously untreated epithelial ovarian cancer","volume":"71","author":"Naumann","year":"1998","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2006.07.036_bib35","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1093\/annonc\/mdg176","article-title":"Phase I study of carboplatin, doxorubicin and weekly paclitaxel in patients with advanced ovarian carcinoma","volume":"14","author":"Hess","year":"2003","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2006.07.036_bib36","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/1097-0142(20001001)89:7<1547::AID-CNCR19>3.0.CO;2-P","article-title":"Paclitaxel, cisplatin, and epirubicin first-line chemotherapy in stage III and IV ovarian carcinoma: long-term results of a phase II study","volume":"89","author":"Papadimitriou","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2006.07.036_bib37","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s002800000271","article-title":"Cisplatin and escalating doses of paclitaxel and epirubicin in advanced ovarian cancer. A phase I study","volume":"48","author":"Nardi","year":"2001","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ygyno.2006.07.036_bib38","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/00001813-200306000-00006","article-title":"Escalating doses of paclitaxel and epirubicin in combination with cisplatin in advanced ovarian epithelial carcinoma: a phase I\u2013II study","volume":"14","author":"Gebbia","year":"2003","journal-title":"Anti-cancer Drugs"},{"key":"10.1016\/j.ygyno.2006.07.036_bib39","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1200\/JCO.1999.17.1.46","article-title":"First-line chemotherapy with epirubicin, paclitaxel, and carboplatin for advanced ovarian cancer: a phase I\/II study of the Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study Group","volume":"17","author":"du Bois","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2006.07.036_bib40","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/sj.bjc.6600259","article-title":"A dose-finding study of carboplatin\u2013epirubicin\u2013docetaxel in advanced epithelial ovarian cancer","volume":"86","author":"O'Neill","year":"2002","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2006.07.036_bib41","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1525-1438.2003.13363.x","article-title":"First-line treatment of ovarian cancer FIGO stages IIb\u2013IV with paclitaxel\/epirubicin\/carboplatin versus paclitaxel\/carboplatin","volume":"13","author":"Kristensen","year":"2003","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2006.07.036_bib42","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1200\/JCO.2005.03.2938","volume":"24","author":"duBois","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2006.07.036_bib43","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S0090-8258(03)00128-8","article-title":"First-line chemotherapy with epidoxorubicin, paclitaxel, and carboplatin for the treatment of advanced epithelial ovarian cancer patients","volume":"89","author":"Romanini","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2006.07.036_bib44","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/sj.bjc.6600250","article-title":"A phase I dose-finding of a combination of pegylated liposomal doxorubicin (Doxil), carboplatin and paclitaxel in ovarian cancer","volume":"86","author":"Gibbs","year":"2002","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2006.07.036_bib45","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1080\/028418602320404998","article-title":"Randomized trial of single agent paclitaxel given weekly versus every three weeks and with oral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum","volume":"41","author":"Rosenberg","year":"2002","journal-title":"Acta Oncol."},{"key":"10.1016\/j.ygyno.2006.07.036_bib46","first-page":"203a","article-title":"A phase II study of Doxil\/Caelyx versus paclitaxel in platinum-treated, taxane-naive relapsed ovarian cancer","volume":"21","author":"O'Bryne","year":"2002","journal-title":"Proc. ASCO"},{"key":"10.1016\/j.ygyno.2006.07.036_bib47","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0090-8258(03)00337-8","article-title":"Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5","volume":"90","author":"Copeland","year":"2003","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825806005877?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825806005877?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,21]],"date-time":"2019-04-21T02:44:48Z","timestamp":1555814688000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825806005877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["S0090825806005877"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2006.07.036","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2007,1]]}}}